RecruitingT-cell LymphomaT-cell Leukemia
CD4CAR for CD4+ Leukemia and Lymphoma
Eligible age
12+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Sponsor: Huda Salman
You may qualify if…
- ✓ In order to be eligible to participate in this study, an individual will be enrolled if they meet the following criteria:
- ✓ 1. Patients must voluntarily sign and date informed consent forms that state his or her willingness to comply with all study procedures and availability for the duration of the study.
- ✓ 2. Age 12 years old or older
- ✓ 3. Subjects with any documented CD4+ T cell hematologic malignancies. Male and female subjects with CD4+ T-cell hematologic malignancies with either relapsed or refractory disease (including those patients who have undergone a prior transplant (if allogeneic, subjects are eligible if there are no remaining donor cells) and patients with an inadequate response after 4-6 cycles of standard chemotherapy) are eligible. Response criteria for each disease subset will be evaluated based on Standard of Care Guidelines.
- ✓ 4. Creatinine clearance of \> 60 ml/min (or otherwise non clinically-significant, per study investigator)
- ✓ 5. ALT/AST \< 3 x ULN
- ✓ 6. Bilirubin \< 2 x ULN
- ✓ 7. No supplemental oxygen at rest Note: Pulmonary Function Test (PFT) only required per treating physician discretion
You may not qualify if…
- ✕ 1. Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential (see definition below) must have a negative serum or urine pregnancy test prior to initiation of conditioning chemotherapy, per research sites' clinical policy.
- ✕ 2. Uncontrolled active infection necessitating systemic therapy.
- ✕ 3. Active hepatitis B or hepatitis C infection. Active hepatitis C is defined as the hepatitis C antibody is positive while quantitative HCV RNA results exceed the lower detection limit.
- ✕ Note the following subjects will be eligible:
- ✕ Subjects with a history of hepatitis B but have received antiviral therapy and have nondetectable viral DNA for 6 months prior to enrollment are eligible
- ✕ Subjects seropositive for HBS antibodies due to hepatitis B virus vaccine with no signs or active infection (Negative HBs Ag, HBc and HBe Ags) are eligible
- ✕ Subjects who had hepatitis C but have received antiviral therapy and show no detectable hepatitis C virus (HCV) viral RNA for 6 months are eligible
- ✕ If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by reverse transcription-polymerase chain reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA) negative.
Where it's recruiting
Source: ClinicalTrials.gov · NCT03829540 · last updated 2026-06-24